Northland Capital Partners reissued their buy rating on shares of Beximco Pharmaceuticals (LON:BXP) in a research note published on Tuesday. The brokerage currently has a GBX 75 ($1.05) target price on the stock.
Separately, Northland Securities reaffirmed a corporate rating on shares of Beximco Pharmaceuticals in a research note on Friday, January 19th.
Shares of BXP opened at GBX 59.60 ($0.84) on Tuesday. Beximco Pharmaceuticals has a 12-month low of GBX 50.38 ($0.71) and a 12-month high of GBX 71.75 ($1.01).
ILLEGAL ACTIVITY NOTICE: “Beximco Pharmaceuticals (BXP) Earns “Buy” Rating from Northland Capital Partners” was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3334361/beximco-pharmaceuticals-bxp-earns-buy-rating-from-northland-capital-partners.html.
Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients. It offers allergic disorder, analgesic and antipyretic, anti-infective, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, intravenous fluid, muscloskeletal, oncology, respiratory, skin care, vitamin and mineral supplement, and other products.
Receive News & Ratings for Beximco Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beximco Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.